These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 31647850)

  • 1. Autoantibody production significantly decreased with APRIL/BLyS blockade in murine chronic rejection kidney transplant model.
    Bath NM; Ding X; Verhoven BM; Wilson NA; Coons L; Sukhwal A; Zhong W; Redfield Iii RR
    PLoS One; 2019; 14(10):e0223889. PubMed ID: 31647850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. APRIL/BLyS Blockade Reduces Donor-specific Antibodies in Allosensitized Mice.
    Wilson NA; Bath NM; Verhoven BM; Ding X; Boldt BA; Sukhwal A; Zhong W; Panzer SE; Redfield RR
    Transplantation; 2019 Jul; 103(7):1372-1384. PubMed ID: 30830041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Desensitization and treatment with APRIL/BLyS blockade in rodent kidney transplant model.
    Bath NM; Ding X; Wilson NA; Verhoven BM; Boldt BA; Sukhwal A; Reese SR; Panzer SE; Djamali A; Redfield RR
    PLoS One; 2019; 14(2):e0211865. PubMed ID: 30735519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APRIL/BLyS deficient rats prevent donor specific antibody (DSA) production and cell proliferation in rodent kidney transplant model.
    Bath NM; Verhoven BM; Wilson NA; Zeng W; Zhong W; Coons L; Djamali A; Redfield RR
    PLoS One; 2022; 17(10):e0275564. PubMed ID: 36227902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Murine islet allograft tolerance upon blockade of the B-lymphocyte stimulator, BLyS/BAFF.
    Parsons RF; Yu M; Vivek K; Zekavat G; Rostami SY; Ziaie AS; Luo Y; Koeberlein B; Redfield RR; Ward CD; Migone TS; Cancro MP; Naji A; Noorchashm H
    Transplantation; 2012 Apr; 93(7):676-85. PubMed ID: 22262127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of BLyS inhibits B-cell responses and antibody production for the prevention of chronic transplant rejection.
    Liao T; Shi X; Han F; Wang Y; Zeng W; Liu R; Yan Z; Xia R; Huang Z; Xu J; Miao Y
    J Heart Lung Transplant; 2024 Apr; 43(4):652-662. PubMed ID: 38070662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease.
    Shi F; Xue R; Zhou X; Shen P; Wang S; Yang Y
    Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):666-673. PubMed ID: 34519594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A mouse model of systemic lupus erythematosus responds better to soluble TACI than to soluble BAFFR, correlating with depletion of plasma cells.
    Haselmayer P; Vigolo M; Nys J; Schneider P; Hess H
    Eur J Immunol; 2017 Jun; 47(6):1075-1085. PubMed ID: 28383107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralizing BAFF/APRIL with atacicept prevents early DSA formation and AMR development in T cell depletion induced nonhuman primate AMR model.
    Kwun J; Page E; Hong JJ; Gibby A; Yoon J; Farris AB; Villinger F; Knechtle S
    Am J Transplant; 2015 Mar; 15(3):815-22. PubMed ID: 25675879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of spontaneous B lymphocyte autoimmunity with adenovirus-encoded soluble TACI.
    Liu W; Szalai A; Zhao L; Liu D; Martin F; Kimberly RP; Zhou T; Carter RH
    Arthritis Rheum; 2004 Jun; 50(6):1884-96. PubMed ID: 15188365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting B-lymphocyte stimulator/B-cell activating factor and a proliferation-inducing ligand in hematologic malignancies.
    Shivakumar L; Ansell S
    Clin Lymphoma Myeloma; 2006 Sep; 7(2):106-8. PubMed ID: 17026820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BLyS neutralization results in selective anti-HLA alloantibody depletion without successful desensitization.
    Agarwal D; Luning Prak ET; Bharani T; Everly M; Migone TS; Cancro M; Allman D; Choe I; Kearns JD; Trofe-Clark J; Naji A; Kamoun M
    Transpl Immunol; 2021 Dec; 69():101465. PubMed ID: 34506905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies against human BLyS and APRIL attenuate EAE development in marmoset monkeys.
    Jagessar SA; Heijmans N; Oh L; Bauer J; Blezer EL; Laman JD; Migone TS; Devalaraja MN; 't Hart BA
    J Neuroimmune Pharmacol; 2012 Sep; 7(3):557-70. PubMed ID: 22870852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the BLyS-APRIL signaling pathway in SLE.
    La Cava A
    Clin Immunol; 2013 Sep; 148(3):322-7. PubMed ID: 23269199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The B Cell-Stimulatory Cytokines BLyS and APRIL Are Elevated in Human Periodontitis and Are Required for B Cell-Dependent Bone Loss in Experimental Murine Periodontitis.
    Abe T; AlSarhan M; Benakanakere MR; Maekawa T; Kinane DF; Cancro MP; Korostoff JM; Hajishengallis G
    J Immunol; 2015 Aug; 195(4):1427-35. PubMed ID: 26150532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4+ T Cell Help Is Mandatory for Naive and Memory Donor-Specific Antibody Responses: Impact of Therapeutic Immunosuppression.
    Chen CC; Koenig A; Saison C; Dahdal S; Rigault G; Barba T; Taillardet M; Chartoire D; Ovize M; Morelon E; Defrance T; Thaunat O
    Front Immunol; 2018; 9():275. PubMed ID: 29515582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus.
    Morel J; Roubille C; Planelles L; Rocha C; Fernandez L; Lukas C; Hahne M; Combe B
    Ann Rheum Dis; 2009 Jun; 68(6):997-1002. PubMed ID: 18676986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TACI-Ig prevents the development of airway hyperresponsiveness in a murine model of asthma.
    Bilsborough J; Chadwick E; Mudri S; Ye X; Henderson WR; Waggie K; Hebb L; Shin J; Rixon M; Gross JA; Dillon SR
    Clin Exp Allergy; 2008 Dec; 38(12):1959-68. PubMed ID: 19037968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TACI-Ig induces immune balance of Th cells in MLN via BLyS/APRIL-receptors signaling in rats with adjuvant-induced arthritis.
    Qin Q; Chang Y; Wang D; Wu Y; Zhang LL; Wei W
    Int Immunopharmacol; 2011 Dec; 11(12):2167-75. PubMed ID: 21996540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BLyS and APRIL in rheumatoid arthritis.
    Seyler TM; Park YW; Takemura S; Bram RJ; Kurtin PJ; Goronzy JJ; Weyand CM
    J Clin Invest; 2005 Nov; 115(11):3083-92. PubMed ID: 16239971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.